EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Signaling through the nicotinic acetylcholine receptor in the liver protects against the development of metabolic dysfunction-associated steatohepatitis

Heejin Jun, Shanshan Liu, Alexander J Knights, Kezhou Zhu, Yingxu Ma, Jianke Gong, Ashley E Lenhart, Xiaoling Peng, Yunying Huang, Jared P Ginder, Christopher H Downie, Erika Thalia Ramos und 4 weitere

PLOS Biology · 2024

DOI: 10.1371/journal.pbio.3002728 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Biology, 2024. Verfasst von Heejin Jun und 15 weiteren Autor:innen. Beteiligte Einrichtung: Life Sciences Institute, University of Michigan, Ann Arbor, Michigan, United States of America. Hauptthemen laut MEDLINE: Receptors, Nicotinic, Liver, Signal Transduction, Fatty Liver. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAAA NIH HHS, NIDDK NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatohepatitis (MASH) is the progressive form of liver steatosis, the most common liver disease, and substantially increases the mortality rate. However, limited therapies are currently available to prevent MASH development. Identifying potential pharmacological treatments for the condition has been hampered by its heterogeneous and complex nature. Here, we identified a hepatic nonneuronal cholinergic signaling pathway required for metabolic adaptation to caloric overload. We found that cholinergic receptor nicotinic alpha 2 subunit (CHRNA2) is highly expressed in hepatocytes of mice and humans. Further, CHRNA2 is activated by a subpopulation of local acetylcholine-producing macrophages during MASH development. The activation of CHRNA2 coordinates defensive programs against a broad spectrum of MASH-related pathogenesis, including steatosis, inflammation, and fibrosis. Hepatocyte-specific loss of CHRNA2 signaling accelerates the disease onset in different MASH mouse models. Activation of this pathway via pharmacological inhibition of acetylcholine degradation protects against MASH development. Our study uncovers a hepatic nicotinic cholinergic receptor pathway that constitutes a cell-autonomous self-defense route against prolonged metabolic stress and holds therapeutic potential for combatting human MASH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, NicotinicLiverSignal TransductionFatty LiverHepatocytesAnimalsHumansMiceMice, Inbred C57BLMaleMacrophagesAcetylcholineMice, KnockoutDisease Models, Animal

Substanzen

Receptors, NicotinicAcetylcholine

Autor:innen und Institutionen

  • Life Sciences Institute, University of Michigan, Ann Arbor, Michigan, United States of America.
  • Department of Nutritional Sciences, College of Human Sciences, Texas Tech University, Lubbock, Texas, United States of America.
  • Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha, China.
  • International Research Center for Sensory Biology and Technology of MOST, Key Laboratory of Molecular Biophysics of MOE, and College of Life Sciences and Technology, and Huazhong University of Science and Technology, Wu…
  • Department of Chemistry, University of Michigan, Ann Arbor, Michigan, United States of America.
  • Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

ORCID-Profile: Jun Wu

Förderung

  • NIAAA NIH HHS
  • NIDDK NIH HHS
  • NIA NIH HHS
  • NIGMS NIH HHS
  • National Institute on Alcohol Abuse and Alcoholism
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institute on Aging
  • National Science Foundation

Zitieren

APA

Jun, H., Liu, S., Knights, A. J., Zhu, K., Ma, Y., Gong, J., Lenhart, A. E., Peng, X., Huang, Y., Ginder, J. P., Downie, C. H., Ramos, E. T., Kullander, K., Kennedy, R. T., Xu, X. Z. S., & Wu, J. (2024). Signaling through the nicotinic acetylcholine receptor in the liver protects against the development of metabolic dysfunction-associated steatohepatitis. PLOS Biology. https://doi.org/10.1371/journal.pbio.3002728

Vancouver

Jun H, Liu S, Knights AJ, Zhu K, Ma Y, Gong J, et al. Signaling through the nicotinic acetylcholine receptor in the liver protects against the development of metabolic dysfunction-associated steatohepatitis. PLOS Biology. 2024. doi:10.1371/journal.pbio.3002728

BibTeX
@article{Jun2024,
  author = {Jun, Heejin and Liu, Shanshan and Knights, Alexander J and Zhu, Kezhou and Ma, Yingxu and Gong, Jianke and Lenhart, Ashley E and Peng, Xiaoling and Huang, Yunying and Ginder, Jared P and Downie, Christopher H and Ramos, Erika Thalia and Kullander, Klas and Kennedy, Robert T and Xu, X Z Shawn and Wu, Jun},
  title = {Signaling through the nicotinic acetylcholine receptor in the liver protects against the development of metabolic dysfunction-associated steatohepatitis},
  journal = {PLOS Biology},
  year = {2024},
  doi = {10.1371/journal.pbio.3002728}
}
Kostenlos starten →